Published in Biomed Res Int on December 16, 2013
Precision in Addiction Care: Does It Make a Difference? Yale J Biol Med (2015) 0.80
Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014. Subst Abuse Treat Prev Policy (2016) 0.75
Comorbid Psychopathology and Alcohol Use Patterns among Methadone Maintenance Treatment Patients. J Addict (2015) 0.75
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med (2000) 6.65
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 3.05
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev (2003) 2.44
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther (2007) 2.06
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther (2006) 1.92
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality (2004) 1.69
Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol (2005) 1.59
Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat (2000) 1.58
Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. J Clin Psychopharmacol (2009) 1.55
Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res (2004) 1.53
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther (2006) 1.49
HIV-1 in Taiwan. Lancet (2007) 1.47
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther (2005) 1.45
Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend (2002) 1.40
The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci (1995) 1.39
Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J Urban Health (2007) 1.21
Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol (2010) 1.21
Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther (2008) 1.20
Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat (2006) 1.20
Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend (2005) 1.20
Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict (2009) 1.20
Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol (1993) 1.18
The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis (2008) 1.16
Essentiality of HIV testing and education for effective HIV control in the national pilot harm reduction program: the Taiwan experience. Kaohsiung J Med Sci (2012) 1.09
Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One (2011) 1.08
Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev (2007) 1.04
Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl) (2004) 1.04
Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain (1991) 1.04
Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2012) 1.04
Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan. Subst Abuse Treat Prev Policy (2011) 1.03
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics (2011) 1.03
Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther (2001) 1.01
Excessive alcohol consumption and drinking expectations among clients in methadone maintenance. J Subst Abuse Treat (2001) 1.01
A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China. Drug Alcohol Depend (2011) 1.00
Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol (2005) 0.99
CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol (2011) 0.97
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol (2011) 0.97
Factors associated with methadone treatment among injection drug users in Bangkok, Thailand. J Subst Abuse Treat (2011) 0.96
Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat (2007) 0.94
Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis (2000) 0.94
Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev (2008) 0.91
CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol (2011) 0.90
Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis (2007) 0.88
HIV drug interactions: the good, the bad, and the other. Ther Drug Monit (2002) 0.82
Enantioselective determination of methadone and its main metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in serum, urine and hair by capillary electrophoresis. Electrophoresis (1997) 0.81
Alcohol use problem among patients in methadone maintenance treatment in Taiwan. J Subst Abuse Treat (2010) 0.80
Road traffic crashes and prescribed methadone and buprenorphine: a French registry-based case-control study. Drug Alcohol Depend (2011) 0.79
Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst Abuse Treat Prev Policy (2012) 0.79
Clinical and epidemiological assessment of substance misuse and psychiatric comorbidity. Curr Opin Psychiatry (2012) 0.76
The challenging interactions between antiretroviral agents and addiction drugs. Am Clin Lab (2002) 0.76